Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Assets: 2014-2024

Historic Non-Current Assets for ImmunityBio (IBRX) over the last 11 years, with Dec 2024 value amounting to $198.3 million.

  • ImmunityBio's Non-Current Assets fell 5.92% to $189.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.5 million, marking a year-over-year decrease of 5.92%. This contributed to the annual value of $198.3 million for FY2024, which is 5.71% down from last year.
  • As of FY2024, ImmunityBio's Non-Current Assets stood at $198.3 million, which was down 5.71% from $210.4 million recorded in FY2023.
  • ImmunityBio's Non-Current Assets' 5-year high stood at $221.8 million during FY2022, with a 5-year trough of $109.7 million in FY2020.
  • For the 3-year period, ImmunityBio's Non-Current Assets averaged around $210.2 million, with its median value being $210.4 million (2023).
  • As far as peak fluctuations go, ImmunityBio's Non-Current Assets soared by 64.81% in 2022, and later declined by 5.71% in 2024.
  • ImmunityBio's Non-Current Assets (Yearly) stood at $109.7 million in 2020, then rose by 22.70% to $134.6 million in 2021, then surged by 64.81% to $221.8 million in 2022, then decreased by 5.15% to $210.4 million in 2023, then declined by 5.71% to $198.3 million in 2024.